8-K: TELA Bio Faces Nasdaq Delisting, Seeks Reverse Stock Split

TELA Bio, Inc. received a notice from Nasdaq indicating its common stock is subject to delisting due to a sustained low bid price, prompting the company to request a hearing and propose a reverse stock split.

Summary

• TELA Bio, Inc. was notified by Nasdaq on September 15, 2026, that its common stock is subject to delisting because the bid price has been below $1.00 for 30 consecutive business days.
• The company did not regain compliance within the 180-day grace period ending September 14, 2026.
• TELA Bio intends to request a hearing before a Nasdaq Hearings Panel to present a plan for regaining compliance.
• A hearing request will stay any delisting action, allowing the stock to remain listed pending the panel's decision.
• To regain compliance, the stock must maintain a bid price of at least $1.00 for 10 to 20 consecutive business days.
• On September 14, 2026, the company filed a proxy statement seeking stockholder approval for a reverse stock split, ranging from 1-for-5 to 1-for-15.
• A special meeting for stockholder approval of the reverse stock split is scheduled for October 8, 2026.
• The company cannot guarantee that the reverse stock split proposal will be approved by stockholders.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development due to the potential delisting from Nasdaq, although the company is actively pursuing a hearing and a reverse stock split to rectify the situation.

Positives

• The company is proactively addressing the delisting notice by requesting a hearing with the Nasdaq Hearings Panel.
• A hearing request will automatically stay any suspension or delisting, allowing continued trading on Nasdaq during the process.
• The company is pursuing a reverse stock split as a potential solution to regain compliance with the minimum bid price requirement.

Negatives

• The company's common stock is subject to delisting from the Nasdaq Global Market due to failing to meet the Minimum Bid Price Requirement.
• The company has not regained compliance with the minimum bid price requirement within the allotted 180-day grace period.
• There is uncertainty regarding stockholder approval of the proposed reverse stock split, which is crucial for regaining compliance.
• The company cannot assure that the proposed reverse stock split will be approved by stockholders.

Risks

• The primary risk is the delisting of the company's common stock from the Nasdaq Global Market if compliance with the Minimum Bid Price Requirement is not achieved.
• Failure to obtain stockholder approval for the proposed reverse stock split could lead to delisting.
• The company's ability to sustain long-term compliance with Nasdaq listing requirements remains a concern.
• Forward-looking statements are subject to considerable risks and uncertainties, including the trading price of the common stock.

Future Outlook

The company's future outlook is contingent on its ability to regain compliance with Nasdaq's Minimum Bid Price Requirement, primarily through a potential reverse stock split and a successful hearing before the Nasdaq Hearings Panel. The company cannot assure that these measures will be successful.

Management Comments

• The Company intends to timely request a hearing before the Panel.
• At such hearing, the Company intends to submit a plan to regain compliance with the Minimum Bid Price Requirement and demonstrate its ability to sustain long term compliance with all applicable continued listing requirements.
• The Company cannot assure you such proposal will be approved by the stockholders at the special meeting.

Industry Context

StockSavvy.ai notes that facing delisting due to low stock price is a common challenge for smaller or struggling companies, often necessitating corporate actions like reverse stock splits to maintain exchange listing and investor confidence.

Stakeholder Impact

• Shareholders: Potential for continued trading on Nasdaq pending the hearing outcome, but risk of delisting if compliance is not achieved. A reverse stock split could reduce the number of shares outstanding but not the overall market capitalization.
• Creditors: Continued listing on Nasdaq may provide more confidence, but delisting could negatively impact perceived financial stability.
• Employees: Uncertainty surrounding the company's listing status could affect morale and confidence.

Next Steps

• Request a hearing before the Nasdaq Hearings Panel.
• Submit a plan to regain compliance with the Minimum Bid Price Requirement at the hearing.
• Hold a special meeting of stockholders on October 8, 2026, to vote on a proposed reverse stock split.
• Await the decision of the Nasdaq Hearings Panel regarding continued listing.

Key Dates

Recommendation

The filing indicates a significant risk of delisting, which is a negative development. However, the company is actively pursuing remedies through a hearing and a potential reverse stock split. The outcome is uncertain, making a 'hold' recommendation appropriate until more clarity is available on the success of these actions.

Keywords

Nasdaq delisting, Minimum Bid Price Requirement, reverse stock split, Nasdaq Hearings Panel, listing compliance, stockholder approval, TELA Bio